Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY announces positive Phase 2 Bracelet-1 results in mBC

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 31, 2023 11:51am

134 Views

Post# 35472660

RE:ONCY announces positive Phase 2 Bracelet-1 results in mBC

Combination Therapy: Combination regimens are difficult to assess without comparing with individual components.

[ONCY's Bracelet-1 Phase 2 study compared pelareorep as a single agent and pelareorep in combination with an immune checkpoint inhibitor demonstrating PFS improvements at 6 months in both treatment arms]

https://www.targetedonc.com/view/fda-draft-guidance-supports-randomized-trials-for-accelerated-approvals

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China